Current report, items 2.02, 8.01, and 9.01



BGCOLOR="WHITE">










UNITED STATES




SECURITIES AND EXCHANGE COMMISSION



Washington, D.C. 20549










FORM

8-K











CURRENT
REPORT




Pursuant to Section 13 or 15(d)




of the Securities Exchange Act of 1934




Date of Report (Date of earliest event reported): April 13, 2021










MEI Pharma, Inc.




(Exact
name of registrant as specified in its charter)







































Delaware





000-50484






51-0407811





(State or other jurisdiction of




incorporation or organization)






(Commission




File Number)






(I.R.S. Employer




Identification No.)





11455 El Camino Real, Suite 250




San Diego, California 92130




(Address of principal executive offices) (Zip Code)




Registrant’s telephone number, including area code:

(858) 369-7100










Check the appropriate box below if the Form

8-K

filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (

see

General Instruction A.2. below):















Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
















Soliciting material pursuant to Rule

14a-12

under the Exchange Act (17
CFR

240.14a-12)

















Pre-commencement

communications pursuant to Rule

14d-2(b)

under the Exchange Act (17 CFR

240.14d-2(b))

















Pre-commencement

communications pursuant to Rule

13e-4(c)

under the Exchange Act (17 CFR

240.13e-4(c))




Securities registered pursuant to Section 12(b) of the Act:


































Title of each class






Trading




Symbol






Name of each exchange




on which registered




Common stock, $0.00000002 par value




MEIP




The NASDAQ Stock Market LLC



Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule

12b-2

of the Securities Exchange Act of 1934

(§240.12b-2

of this chapter).



☐ Emerging growth company



☐ If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the Exchange Act.


















Item 2.02. Results of Operations and Financial Condition.



The information set forth below under “Investor Presentation” in Item 8.01 below is incorporated by reference herein.




Item 8.01 Other Events.




Investor Presentation



MEI Pharma, Inc. (the “Company”) is furnishing this Current Report on Form

8-K

in connection with
the disclosure of information contained in an investor presentation to be used by the Company at various meetings with institutional investors and analysts. A copy of the presentation is filed herewith as Exhibit 99.1 and is incorporated into this
Item 8.01 by reference.




Press Release



On
April 13, 2021, the Company and Kyowa Kirin issued a press release titled “MEI Pharma Announces Completion of Patient Enrollment in Follicular Lymphoma Primary Efficacy Population of Global Phase 2 TIDAL Study Intended to Support Potential
Accelerated Approval Application from U.S. Food and Drug Administration (FDA)”. A copy of the press release is filed herewith as Exhibit 99.2 and is incorporated into this Item 8.01 by reference.




Poster Presentation



On April 10, 2021, the Company
posted a poster presentation titled “Voruciclib, a CDK9 inhibitor, downregulates MYC and inhibits proliferation of KRAS mutant cancers in preclinical models” on the Company’s website. A copy of the press release is filed herewith as
Exhibit 99.3 and is incorporated into this Item 8.01 by reference.




Item 9.01 Financial Statements and Exhibits.




(d) Exhibits.















































Exhibit No.





Description





99.1



Investor Presentation




99.2



Press release dated April 13, 2021




99.3



Poster Presentation titled “Voruciclib, a CDK9 inhibitor, downregulates MYC and inhibits proliferation of KRAS mutant cancers in preclinical models”












Signatures



Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

































MEI PHARMA, INC.




By:





/s/ Daniel P. Gold






Daniel P. Gold






Chief Executive Officer




Dated: April 13, 2021




The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever MEI Pharma makes a similar move, sign up!

Auto Refresh